Background: Concern remains that ertapenem use may promote cross-resistance in Pseudomonas aeruginosa to antipseudomonal carbapenems (APCs). This study extends our earlier multicentre investigation of this relationship by an additional 3 years.
Introduction
Because ertapenem has a similar spectrum of microbiological activity to imipenem and meropenem against Enterobacteriaceae, Gram-positive species and anaerobes, but little activity against Pseudomonas aeruginosa, and because in vitro studies have demonstrated that it is possible for ertapenem to select resistance to other carbapenems in this important nosocomial pathogen, concern has been raised that widespread use of ertapenem may amplify the selection of resistance in P. aeruginosa.
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While several single-centre studies had identified no association between volume of ertapenem use and reduced carbapenem susceptibility in P. aeruginosa, no multicentre investigations had been published as of 2008. 4 -7 To address this, we conducted the Ertapenem Utilization and Resistance Emergence among Collateral Antimicrobials (EURECA) study, which evaluated the association between ertapenem use and the change in the proportion of carbapenem-resistant P. aeruginosa at 25 hospitals for a period of 6 years; 3 years preadoption and 3 years post-adoption of ertapenem. 8 In this article, we report results from an extension of that investigation including data collected at each site for up to 9 years.
Methods
Study methods were described in full in the publication of the original EURECA investigation, but will be recapitulated here in brief. 8 Both the original EURECA investigation and this extension study were reviewed by our Institutional Review Board. The investigators established an algorithm to identify the first calendar year of ertapenem use based on drug purchase records; i.e. at least three-quarters of purchases in that year. For each participating site, drug utilization data (total grams purchased) were obtained for the 3 years prior to the first year of use-denoted herein as # The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2011; 66: 1392 -1395 doi:10.1093/jac/dkr141 Advance Access publication 1 April 2011 study years 1 -3-and for the 6 years after ertapenem adoption (inclusive of the first calendar year of use)-study years 4 -9. This structure was created to evaluate the potential effect of ertapenem adoption at multiple hospitals though they did not adopt the agent simultaneously. These data were provided by Premier, Inc. (Charlotte, NC, USA). Through its consulting relationships, Premier, Inc. also obtained susceptibility data derived from hospital antibiograms for the 9 years relevant to each participating hospital. For the extension study, originally participating sites were asked to provide antibiograms-and purchase data were 
Evaluation of antimicrobial use
In addition to ertapenem, utilization data were obtained for the antipseudomonal carbapenems doripenem, imipenem and meropenem, as well as selected fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin), aminoglycosides (gentamicin and tobramycin) and additional b-lactam antibiotics (ceftazidime, cefepime and piperacillin/tazobactam). An annual use density ratio (UDR) was calculated for each compound at each site as follows: total grams of drug purchased divided by WHO defined daily dose (DDD), with the quantity then divided by the total patient-days for that site, normalized to 1000 days (i.e. per 1000 patient-days). For purposes of analysis, drugs were grouped into a single UDR for each antibiotic class per study year.
Evaluation of P. aeruginosa susceptibility
Susceptibility to the antipseudomonal carbapenems imipenem and meropenem was derived from each hospital's annual antibiogram and measured as the reported proportion of susceptible isolates (percentage susceptible). Because the identity of the sites was blinded to the investigators, available data consisted of only those agents that the site chose to report on its antibiogram for the calendar year. In order to accommodate intermittent reporting and formulary changes, a composite variable of imipenem and meropenem susceptibility was used as the dependent variable in the analysis, created as follows: if imipenem susceptibility was reported, it was assigned as the value for carbapenem susceptibility for that site in that year; and if imipenem was not reported, meropenem susceptibility was used.
Statistical analysis
Results were analysed using SAS v. 9.1 (SAS, Inc., Cary, NC, USA). A mixed model repeated measures ANOVA was used to examine the association between 9 year carbapenem susceptibility and ertapenem UDR while controlling for use of other drug classes thought to confound this relationship.
Results
All 25 hospitals reported at least 4 years of post-adoption data, with 22 of 25 reporting 5 years and 18 of 25 reporting 6 years. Total antibiotic purchases for the cohort, expressed as the sum of the UDRs for all sites, increased over the course of the study (year/total UDR) (n¼ 25 sites unless otherwise indicated): 1/11267; 2/8504; 3/7942; 4/8680; 5/8519; 6/11003; 7/17206; 8/15397 (n¼ 22); 9/10012 (n¼ 18).
Ertapenem purchases by hospital for the cohort increased from a mean UDR of 7.27 in year 4 (the year of ertapenem adoption) to a mean UDR of 15.93 in year 9. The mean UDR for the antipseudomonal carbapenems was 10.39 in year 1, peaked at 18.77 in year 6 and then declined to 15.27 in year 9. With respect to other antibiotic classes, the mean UDR in years 1, 4 and 9 (beginning, year of ertapenem adoption and end of study The mean carbapenem susceptibility declined from 85.4% in year 1 to 81.0% in year 9. Figure 1 displays the mean carbapenem percentage susceptibility along with the mean ertapenem UDR and mean carbapenem UDR for the 9 years of the study. 
Ertapenem
Other carbapenems Susceptibility Figure 1 . Mean carbapenem use and P. aeruginosa susceptibility at 25 hospitals during the 9 years surrounding adoption of ertapenem.
Ertapenem and antipseudomonal potency JAC Table 1 displays number of beds, ertapenem UDR and carbapenem susceptibility for each hospital individually. The repeated measures model found no significant change in mean carbapenem susceptibility over the 9 years of the study (P ¼ 0.99). Ertapenem UDR was not associated with 9 year change in carbapenem susceptibility (P ¼0.54) while controlling for use of other carbapenems, aminoglycosides, fluoroquinolones and other b-lactam antibiotics. No other class was significantly associated with 9 year change in carbapenem susceptibility (P.0.5 for each).
Discussion
Increasing resistance in P. aeruginosa to the carbapenems has been reported, and successful treatment remains an ongoing concern. 6, 9, 10 Strategies to mitigate the spread of resistant isolates such as stewardship programmes, appropriate antibiotic selection and dosing, and adequate infection control are being continually evaluated, as are the mechanisms and sources of resistance development. The EURECA studies sought to examine the possibility that increasing ertapenem use may be associated with change in antipseudomonal carbapenem susceptibility of P. aeruginosa over time. Our multicentre study found no significant change in P. aeruginosa susceptibility over 9 years. Additionally, as illustrated in Table 1 , even among individual sites no consistent pattern was discernable between ertapenem utilization and changes in P. aeruginosa susceptibility. Further, the observed 4% decline in susceptibility for the cohort was not associated with ertapenem use, although such use increased continuously during the study period, as did antibiotic use overall. Our study controlled for other antibiotic classes whose use has been shown to influence carbapenem resistance in P. aeruginosa-particularly fluoroquinolones; however, our methodology could not evaluate either the nature of ertapenem use (e.g. prophylaxis versus treatment, extended-spectrum b-lactamase treatment only etc.) or stewardship or infection control practices at the different sites. Goldstein et al. 5 recently reported an association between declining imipenem use and increasing P. aeruginosa susceptibility to imipenem following a formulary substitution of ertapenem for ampicillin/sulbactam as part of a stewardship programme at their institution. In our study, ertapenem represented a greater share of total carbapenem use by year 9 compared with year 4, while use of all carbapenems collectively increased in quantity but remained 6% of total antibiotic use measured. (Note that we measured only agents commonly used to target P. aeruginosa, but did not include other frequently used compounds, especially other b-lactams.) In particular, imipenem use decreased slightly in total quantity while meropenem use increased (data not shown). Because our statistical model controlled for antibiotic use by class rather than agent, we can state that the use of other carbapenems was not associated with susceptibility, but cannot make the same assertion for any particular carbapenem agent; as such, it is unclear whether Goldstein's findings hold true for our cohort. However, an interaction term between ertapenem use and the use of other carbapenems was non-significant, indicating that the effect of ertapenem use on susceptibility was not dependent on the level of other carbapenem use. Also of interest is that fluoroquinolones were the most frequently used class, and their use increased substantially in the final 3 years of the study; this reflected increases in ciprofloxacin and moxifloxacin use in particular (data not shown).
Antibiotic resistance development is multifactorial; in addition to institution-driven efforts to limit the spread of resistant isolates, the particular mixture of antibiotic agents, the method in which they are used and the patient population to which they are dispensed may all contribute to fluctuating levels of susceptibility. Important limitations of our study include: (i) inability to account for site-specific factors such as infection control or stewardship measures; (ii) using purchased quantities of drug as a proxy for dispensed quantities; and (iii) inability to control for differences in laboratory reporting practices underlying the antibiograms (e.g. elimination of duplicate cultures). Contributing sites were all adult acute care hospitals; we inherently assume that the DDD fairly accounts for drug use across hospitals. The year of ertapenem adoption was designated study year 4. This permitted comparison across hospitals even though they did not adopt the drug during the same calendar year. c Study end represents calendar year 2008 for all hospitals. For the earliest adopters of ertapenem (n¼18), this constitutes year 9 of the study. For those adopting later, it constitutes either year 8 (n¼4) or year 7 (n¼3).
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Patient-level data could mitigate some of these limitations; moreover, it could elucidate the use -susceptibility relationship within the host. Our study identified no association between ertapenem use and decline in P. aeruginosa susceptibility to antipseudomonal carbapenems, despite the fact that mean ertapenem use by the hospitals nearly equalled antipseudomonal carbapenem use by the end of the study period. Further, carbapenems represented a small proportion of antibiotics used at the study sites. While it is important to avoid the ecological fallacy that what is true for the aggregate can be assumed for the individual, the present findings suggest that wider use of ertapenem is not associated with P. aeruginosa resistance at the institutional level. Patient-level data warrant further investigation.
